Global law firm Goodwin today announced that Allison Nicklin, Alicia Palladino, Justin Platt, and Laura Umbrecht joined the firm’s Life Sciences practice as partners in New York and the newly established Philadelphia offices. Their arrival follows the previously announced team of 14 partners, led by partners Rachael Bushey, John Jones, and Thomas Gallagher, who recently joined Goodwin.
“Last week, we welcomed a market-leading team that is extremely well-connected and well-versed in several industries where we focus – healthcare, life sciences, and private equity – across transactional, regulatory, and litigation practices,” said Mitchell Bloom, Chair of Goodwin’s Life Sciences practice. “Allison, Alicia, Justin, and Laura are key members of this team, and we are delighted to welcome them to Goodwin this week, as we continue to invest in both our mid-Atlantic and global platform for the benefit of our clients.”
Nicklin advises public and private pharmaceutical, biotechnology, and medical device companies in mergers, acquisitions, corporate governance, licensing and collaboration transactions, and other strategic transactions. She also represents life sciences companies in private placements, venture capital, and other capital-raising transactions.
Palladino has extensive experience prosecuting patents in the United States and globally in areas of pharmaceutical sciences, nutraceuticals, biologics, dermatological compositions, and cosmetics.
Platt’s practice focuses on health sciences, capital markets, and corporate matters. He represents issuers and underwriters in a variety of corporate finance transactions, including initial public offerings and other public and private offerings of debt, equity, and preferred securities.
Umbrecht represents public and private pharmaceutical, biotechnology, pharma services, and medical device companies in connection with mergers, acquisitions and other corporate transactions, including leveraged buyouts, reverse mergers and de-SPAC transactions, asset purchases, joint ventures, carve-outs and divestitures, co-investments and licensing, development and collaboration transactions. In addition, she advises clients on a variety of corporate governance and securities law matters.
“Goodwin is uniquely positioned to serve clients at the busy intersection of capital and innovation. The Philadelphia market sits squarely within this intersection for biotech, healthcare and pharmaceutical companies, entrepreneurs, and investors,” said Rachael Bushey, co-chair of Goodwin’s Philadelphia office. “Allison, Alicia, Justin and Laura, together with our existing team, extend their expertise and the depth of Goodwin’s global platform to this vibrant market.”
Goodwin’s Life Sciences practice works with companies throughout the corporate lifecycle – from startup and commercial-stage to maturity – as well as investors, banks, and others in the life sciences ecosystem. The Healthcare private equity and regulatory practice advises private equity firms and their portfolio companies, providers, digital health companies, women’s health and wellness companies, and investors on transactions, regulations, government investigations, and litigation. Goodwin has a long record of successfully defending clients in False Claims Act litigation and fraud and abuse investigations as well as on matters involving reimbursement disputes and disclosures to proactively mitigate risks.